Trials / Completed
CompletedNCT02284607
A Study of High Dose MHAA4549A in Healthy Volunteers
A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF HIGH DOSE MHAA4549A IN HEALTHY VOLUNTEERS
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This Phase 1, randomized, double-blind, placebo-controlled study will evaluate the safety, tolerability and pharmacokinetics of two, single intravenous (IV) high doses of MHAA4549A as compared to placebo when administered to healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MHAA4549A | MHAA4549A single, intravenous dose administration, lower dose level |
| DRUG | MHAA4549A | MHAA4549A single, intravenous dose administration, higher dose level |
| DRUG | Placebo | Matching placebo to MHAA4549A administration |
Timeline
- Start date
- 2014-11-03
- Primary completion
- 2015-03-13
- Completion
- 2015-03-13
- First posted
- 2014-11-06
- Last updated
- 2017-03-09
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT02284607. Inclusion in this directory is not an endorsement.